For example, although the neprilysin inhibitors ecadotril, racecadotril, and candoxatril fail to treat heart disease and hypertension effectively [7–9], many clinical studies have shown that omapatrilat, which inhibits various proteases including neprilysin, angiotensin-converting enzyme (ACE), and aminopeptidase, effectively treats hypertension. This evidence concerns the gene MME and heart disorder.